Trueblood Wealth Management LLC Acquires Shares of 15,385 Pfizer Inc. (NYSE:PFE)

Trueblood Wealth Management LLC bought a new stake in shares of Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 15,385 shares of the biopharmaceutical company’s stock, valued at approximately $443,000.

A number of other institutional investors have also added to or reduced their stakes in PFE. Moneta Group Investment Advisors LLC boosted its holdings in shares of Pfizer by 89,592.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after acquiring an additional 160,963,976 shares during the period. Norges Bank bought a new position in Pfizer during the 4th quarter valued at approximately $3,150,472,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Pfizer by 10.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after acquiring an additional 9,393,992 shares during the period. Morgan Stanley grew its stake in shares of Pfizer by 10.3% in the 4th quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock worth $4,073,547,000 after buying an additional 7,419,929 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of Pfizer in the 1st quarter worth approximately $311,238,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on PFE shares. Barclays decreased their target price on Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a report on Thursday, December 14th. Guggenheim began coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research note on Thursday, January 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Friday, March 1st. Finally, UBS Group dropped their price objective on shares of Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a report on Thursday, December 14th. Twelve equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus price target of $36.88.

Pfizer Price Performance

Shares of NYSE:PFE traded down $0.03 during trading on Thursday, reaching $27.75. The company had a trading volume of 39,637,859 shares, compared to its average volume of 43,829,785. The company has a fifty day moving average of $27.47 and a two-hundred day moving average of $29.47. The stock has a market capitalization of $157.14 billion, a P/E ratio of 77.25, a price-to-earnings-growth ratio of 1.24 and a beta of 0.61. Pfizer Inc. has a 12 month low of $25.61 and a 12 month high of $42.22. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. During the same period last year, the company posted $1.14 EPS. The company’s quarterly revenue was down 41.3% compared to the same quarter last year. Equities research analysts forecast that Pfizer Inc. will post 2.22 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.